Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hang Quach

Showing results (71-80 of 119) with videos related to

Pageof 12
Sort By:
Ejhaem|August 21, 2023
The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)Kenneth Jc Lim, Cameron Wellard, Dipti Talaulikar, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 13, 2026
Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk GroupsGhassan Zammar, Bradley Augustson, Elizabeth Moore, et al.
Blood Cancer Journal|January 25, 2022
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trialMeletios A Dimopoulos, Fredrik Schjesvold, Vadim Doronin, et al.
Blood Advances|December 31, 2021
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 studyGareth P Gregory, Shaji Kumar, Ding Wang, et al.
American Journal of Hematology|July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular EventsEvangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.
Scientific Reports|March 9, 2018
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myelomaNicholas A Gherardin, Liyen Loh, Lorenztino Admojo, et al.
Blood Cancer Journal|December 27, 2025
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCOGurdeep Parmar, Marcelo Capra, Fernanda Seguro, et al.
Internal Medicine Journal|August 8, 2017
Bisphosphonate guidelines for treatment and prevention of myeloma bone diseaseOi Lin Lee, Noemi Horvath, Cindy Lee, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple MyelomaMeletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, et al.
Haematologica|June 30, 2022
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cellsKelden Richardson, Simon P Keam, Joe Jiang Zhu, et al.
Pageof 12

Showing results (71-80 of 119) with videos related to

Sort By:
Pageof 12
Ejhaem|August 21, 2023
The prognostic impact of t(11;14) in multiple myeloma: A real-world analysis from the Australian Lymphoma Leukaemia Group (ALLG) and the Australian Myeloma and Related Diseases Registry (MRDR)Kenneth Jc Lim, Cameron Wellard, Dipti Talaulikar, et al.
Clinical Lymphoma, Myeloma & Leukemia|January 13, 2026
Cytogenetic Testing in Newly Diagnosed Multiple Myeloma: Real World Evidence on Clinical Features and Adverse Outcomes for High Risk GroupsGhassan Zammar, Bradley Augustson, Elizabeth Moore, et al.
Blood Cancer Journal|January 25, 2022
Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trialMeletios A Dimopoulos, Fredrik Schjesvold, Vadim Doronin, et al.
Blood Advances|December 31, 2021
Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 studyGareth P Gregory, Shaji Kumar, Ding Wang, et al.
American Journal of Hematology|July 28, 2025
Practical Guidance on Clinical Management of Belantamab Mafodotin-Associated Ocular EventsEvangelos Terpos, Suzanne Trudel, María-Victoria Mateos, et al.
Scientific Reports|March 9, 2018
Enumeration, functional responses and cytotoxic capacity of MAIT cells in newly diagnosed and relapsed multiple myelomaNicholas A Gherardin, Liyen Loh, Lorenztino Admojo, et al.
Blood Cancer Journal|December 27, 2025
Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCOGurdeep Parmar, Marcelo Capra, Fernanda Seguro, et al.
Internal Medicine Journal|August 8, 2017
Bisphosphonate guidelines for treatment and prevention of myeloma bone diseaseOi Lin Lee, Noemi Horvath, Cindy Lee, et al.
The New England Journal of Medicine|June 3, 2024
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple MyelomaMeletios Athanasios Dimopoulos, Meral Beksac, Ludek Pour, et al.
Haematologica|June 30, 2022
The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cellsKelden Richardson, Simon P Keam, Joe Jiang Zhu, et al.
Pageof 12